CamCare™ Assistance Program
For Healthcare Professionals
CamCare is a support program consisting of registered nurses and trained insurance consultants who are available to help you support your patients and their caregivers during Campath® (Alemutuzmab) treatment.
Call the CamCare Support Line 1-800-473-5832 for timely and accurate assistance with the following services:
Nursing Support
24 hours/day, 7 days/week, 365 days/year
As part of CamCare, registered nurses certified in oncology are available to:
- Help answer questions that health care professionals, patients or caregivers may have on CLL or Campath therapy. Nurses are available by telephone 24 hours a day, 7 days a week, 365 days a year
- Provide in-service training programs for your healthcare staff
- Assist with administering Campath in your office
Insurance Assistance
9:00 AM to 5:00 PM, EST (Monday - Friday)
CamCare consultants are available to:
- Provide answers regarding policy coverage questions
- Research patient-specific insurance coverage
- Assist with claims preparation
- Assist in identifying appropriate claims appear strategies
- Identify available payment sources for insured or underinsured patients
Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS
Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].
Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].
Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].
The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.
Please see Full Prescribing Information (PDF).
